Novavax’s Pending EUA Likely Less Important Than Future Updates
Executive Summary
Upcoming booster, adolescent data may be more commercially significant for the vaccine, which would enter a US market with few willing adults still unvaccinated. The tough prospects for one of the first COVID vaccines in development is a lesson in the importance of avoiding regulatory delays.
You may also be interested in...
Pfizer/BioNTech Bolster Case For Omicron Vaccines
The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.
Sanofi/GSK Next-Generation COVID-19 Vaccine Shows Promise As Booster
Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern.
COVID-19 Vaccines In Five And Younger Could Get Earlier FDA Advisory Committee Review
Peter Marks says agency will proceed to meeting once Pfizer and/or Moderna complete their submissions and that the two may be considered at the same VRBPAC panel. FDA's effectiveness standard has not changed, CBER director says, but acknowledges that vaccines might be a little less effective than 50% in subpopulations.